Vaxcyte, Inc.

Contributing Author

Recent Articles by Vaxcyte, Inc.

1 hour	Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study PCVX GlobeNewswire
Sep-30	Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services PCVX GlobeNewswire
Sep-03	Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose PCVX GlobeNewswire
Aug-06	Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) PCVX GlobeNewswire
May-07	Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update PCVX GlobeNewswire
May-01	Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors PCVX GlobeNewswire